AstraZeneca’s MedImmune unit has announced a joint venture (JV) with WuXi AppTec, to develop and market the experimental biological drug MEDI5117 in China. MEDI5117 is a fully human monoclonal ...

Big drugmakers such as AstraZeneca, meanwhile, are working to create separate supply chains for China and the West. Amicus ...

MSD and WuXi Biologics – which have been collaborating ... Alzheimer's therapy donanemab as well as other biologics, and AstraZeneca's recently opened, $360 million active pharmaceutical ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...